Good morning, everyone, and nice to see you again after a few days of running around the equivalent of Woodstock for ravenous biopharma executives and investors. Now, though, the spectacle is winding down and we are returning to something resembling our usual routine, although we confess that we will take a break tomorrow, so a colleague will fill in during our absence. Meanwhile, here are some tidbits to help you focus on your own journey. Hope all goes well and do drop us a line if something interesting, unusual or scandalous occurs …

U.S. government officials are growing concerned that biologic makers are using scare tactics to ward off biosimilar versions of their products, The Washington Post reports. “I am worried that there are either deliberate or unintentional efforts by branded companies to create confusion,” says Food and Drug Administration Commissioner Scott Gottlieb. The campaign of confusing, mixed messages has been underway for years but is attracting greater attention as market competition edges closer to reality.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Interesting quote from Philip Schneider (Advisory Board Chair, Alliance for Safe Biologic Medicines) in the WAPO item on “scare tactics” – “The U.S. medical community should proceed cautiously with moving patients to unbranded biologics “so we don’t end up with another thalidomide’’ … ”
    One wonders how the former-Celgene, now BMS will feel about such a position?
    (To explain – Celgene’s Revlimid product sales were $10 Billion of their $15 Billion 2018 revenue. It is the thalidomide based product that gave the industry the Risk Evaluation and Mitigation Strategies (REMS) – both beloved and despised, depending on where one sits in this dance,)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy